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Hetero-oligomerization between the TNF receptor
superfamily members CD40, Fas and TRAILR2
modulate CD40 signalling
Cristian R Smulski*,1,2,3, Marion Decossas1, Neila Chekkat1,6, Julien Beyrath1, Laure Willen2, Gilles Guichard4,
Raquel Lorenzetti3, Marta Rizzi3,5, Hermann Eibel3, Pascal Schneider*,2,7 and Sylvie Fournel*,1,6,7
TNF receptor superfamily members (TNFRSF) such as CD40, Fas and TRAIL receptor 2 (TRAILR2) participate to the adaptive
immune response by eliciting survival, proliferation, differentiation and/or cell death signals. The balance between these signals
determines the fate of the immune response. It was previously reported that these receptors are able to self-assemble in the
absence of ligand through their extracellular regions. However, the role of this oligomerization is not well understood, and none of
the proposed hypotheses take into account potential hetero-association of receptors. Using CD40 as bait in a flow cytometry
Förster resonance energy transfer assay, TNFRSF members with known functions in B cells were probed for interactions. Both Fas
and TRAILR2 associated with CD40. Immunoprecipitation experiments confirmed the interaction of CD40 with Fas at the
endogenous levels in a BJAB B-cell lymphoma cell line deficient for TRAILR2. TRAILR2-expressing BJAB cells displayed a robust
CD40–TRAILR2 interaction at the expense of the CD40–Fas interaction. The same results were obtained by proximity ligation assay,
using TRAILR2-positive and -negative BJAB cells and primary human B cells. Expression of the extracellular domains of Fas or
TRAILR2 with a glycolipid membrane anchor specifically reduced the intrinsic signalling pathway of CD40 in 293T cells.
Conversely, BJAB cells lacking endogenous Fas or TRAILR2 showed an increased NF-κB response to CD40L. Finally, upregulation
of TRAILR2 in primary human B cells correlated with reduced NF-κB activation and reduced proliferation in response to CD40L.
Altogether, these data reveal that selective interactions between different TNFRSF members may modulate ligand-induced
responses upstream signalling events.
Cell Death and Disease (2017) 8, e2601; doi:10.1038/cddis.2017.22; published online 9 February 2017
Germinal centres (GCs) are unique sites in peripheral
lymphoid tissue where clonal selection of B-lymphocytes
takes place in response to antigen stimulation. B-cell clonal
selection results in differentiation of high-affinity B memory
and antibody-secreting cells that permit an efficient secondary
immune response.1–3 At the same time, GCs are known to be
a major source of B-cell lymphomas including follicular and
Burkitt's and also some diffuse large B-cell lymphoma.4,5 In
the process of antibody affinity maturation that takes place in
GCs, B-lymphocytes with low-affinity antigen receptor are
eliminated by apoptosis, whereas those with higher affinity are
selected and survive. The study of how apoptotic signals
synchronize in the regulation of B-cell death in GC will
contribute not only to a better understanding of the mechan-
isms supporting clonal selection of B-lymphocytes and high-
affinity antibody production but also of lymphomagenesis or
progression of B lymphomas of GC origin.
Several reports showed that Fas (CD95 or TNFRSF6), a
pro-apoptotic TNF receptor (TNFR) superfamily member
(TNFRSF), is directly involved in the clonal selection of GC
B-lymphocytes.6–8 Other pro-apoptotic members of the same
family, TRAIL receptors are also expressed in GC
B-lymphocytes.9 In humans, there are four membrane-bound
TRAIL receptors: two death receptors TRAIL receptor 1
(TRAILR1) and TRAILR2 (DR4 or TNFRSF10A and DR5 or
TNFRSF10B, respectively) that mediate death signals and
two decoy receptors TRAILR3 and TRAILR4 (DcR1 or
TNFRSF10C and DcR2 or TNFRSF10D, respectively). Inter-
estingly, Fas or TRAILR-mediated apoptosis is controlled or
counterbalanced in GC cells by another TNFR superfamily
member CD40 (TNFRSF5).10–13 It is conventionally accepted
that CD40-induced protection against Fas or TRAILR-
mediated apoptosis required NF-κB activation and upregula-
tion of anti-apoptotic c-FLIP and Bcl-XL proteins.
12,14–16
However, Benson et al.17 described a rapid CD40-mediated
rescue from Fas-induced apoptosis that did not require NF-κB
activation, was independent of de novo protein synthesis but
was dependent upon active PI3K. Both previously described
rescue mechanisms are ligand dependent, raising the
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question whether the relative amount of receptors may impact
directly on CD40 signalling in a ligand-independent way.
Several TNFRSF members are able to self-associate, in
particular Fas, TRAILRs and CD40.18–23 We previously
reported that CD40 can form non-covalent dimers in the
absence of ligand, with an important contribution of
the extracellular region to establish contacts.23 However, the
potential for different TNFR family members to heteromerize
has not been investigated. In this study, we identified selective
interactions between CD40 and Fas, and between CD40 and
TRAILR2. These heteromers also form at the endogenous
level, and appear to be dynamic, driven by the preferential
association of CD40 with TRAILR2 over Fas. The impact of
heteromer formation on CD40 signalling was studied in cell
lines and in primary human B cells, showing that they can
negatively regulate CD40L-induced responses. Thus, hetero-
mer formation between receptors with opposite functions
could represent the most apical regulation of TNFRSF
signalling.
Results
CD40 interacts with Fas and TRAILR2. The first evidence
of CD40–Fas interaction was obtained by Förster resonance
energy transfer (FRET) by flow cytometry. Fas was initially
predicted to serve as a negative control for CD40–CD40
interaction, but yielded high FRETrates when it was co-trans-
fected with CD40 (Figure 1a). Then, we tested the ability of
CD40 to interact with other TNFRSF members important for
B-cell function such as Fas, TRAILR1, TRAILR2, BCMA
(TNFRSF17), BAFFR (BR3 or TNFRSF13C), TACI
(TNFRSF13B) and the two unrelated receptors ErbB1 and
ErbB2. No interaction could be detected with ErbB1, ErbB2,
TRAILR1, TACI, BAFFR or BCMA. However, positive FRET
responses were observed between CD40 and Fas and, to a
lesser extent, between CD40 and TRAILR2 (Figure 1b).
Ligand-independent associations of CD40 with itself, with Fas
and with TRAILR2 were readily observed with constructs
lacking the intracellular domain (ΔICD), indicating that the
latter is not required for the observed homo- and hetero-
oligomerizations (Figure 1c). No interaction was detected
between Fas and TRAILR2. In summary, in transiently
transfected 293T cells, CD40 interacts with Fas and TRAILR2
as detected by FRET and these interactions do not require
the intracellular domains.
CD40 selectively interacts with TRAILR2 over Fas. In
order to visualize these interactions in cells with endogenous
expression levels, the CD40-positive and Fas-positive B-cell
lymphoma cell line BJAB, with or without expression of
TRAILR2, was used.24 Immunocytochemistry using antibo-
dies against the ectodomains of CD40, Fas and TRAILR2
showed colocalization at the cell surface between CD40 and
Fas in TRAILR2-negative BJAB cells. However, colocaliza-
tion of CD40 and Fas was reduced in TRAILR2-positive BJAB
when compared with TRAILR2-negative BJAB cells, despite
similar Fas expression levels. Under the same conditions,
colocalization of CD40 and TRAILR2 was detected in
TRAILR2-positive BJAB cells (Figure 2, Supplementary
Figures 1 and 2).
In line with these results, we found that CD40 and Fas co-
immunoprecipitated in native membrane fractions of
TRAILR2-negative BJAB cells, but that this interaction was
strongly decreased in TRAILR2-positive cells, which instead
showed co-immunoprecipitation of CD40 with TRAILR2
(Figure 3a). We next assessed these interactions by means
of proximity ligation assays (PLAs),25 using the same primary
antibodies used for immunocytochemistry. This technique
allows the detection of interacting proteins at endogenous
levels by connecting two protein-specific antibodies in close
proximity with a complementary DNA probe that is annealed,
amplified and visualized as a fluorescent spot. We found
CD40-Fas spots on TRAILR2-negative BJAB cells and, as
expected, only background CD40-TRAILR2 spots (Figures 3b
and d). Interestingly, the number of CD40-Fas spots was
significantly diminished in TRAILR2-positive BJAB cells, with
a concomitant appearance of CD40-TRAILR2 spots
(Figures 3c and d). These results, together with those of the
co-immunoprecipitation experiments, indicate that these
interactions can be found at the endogenous levels, and that
CD40 selectively associates with TRAILR2 over Fas in
BJAB cells.
CD40 interacts with Fas and TRAILR2 in primary human
B cells. To investigate whether CD40 associates with Fas
and TRAILR2 in primary human B cells, peripheral B-lym-
phocytes were isolated and activated with two different
protocols. Without stimulation, these cells express high levels
of CD40, low levels of Fas and no detectable TRAILR2
(Figure 4a). Treatment with PMA and ionomycin induced a
mild activation profile characterized by increased MHC II
expression but little changes in CD86 levels, associated with
a strong upregulation of Fas but not TRAILR2 (Figures 4a, b,
g and h). In contrast, treatment with an anti-BCR antibody
(anti-IgM/IgG) plus CD40L induced a strong activation profile
characterized by increased levels of both MHC II and CD86,
associated with a mild increase of Fas and TRAILR2 levels
(Figures 4d, e, g and h). These stimulation protocols
somewhat reproduce the situation of TRAILR2-positive and
-negative BJAB cells, although the expression levels of Fas
were decreased when TRAILR2 levels were increased and,
consequently, the percentage of CD40 and Fas double-
positive cells was reduced when the percentage of CD40 and
TRAILR2-positive cells was increased (Figures 4b and e).
PLA assays on activated human B cells detected the
interaction of CD40 with Fas in the absence of TRAILR2
(PMA/ionomycin activation). This interaction was strongly
reduced when less Fas was expressed (BCR/CD40L activa-
tion); it is possible that the concomitant increase in TRAILR2
expression may contribute to further reduce this signal
(Figures 4a-c). In line with the low expression of TRAILR2
after PMA/ionomycin activation, little CD40-TRAILR2 spots
were present in this condition but a slight, yet significant
increase of CD40-TRAILR2 spots was observed when a
modest upregulation of TRAILR2 was achieved by
stimulation with BCR/CD40L (Figures 4d-f). Similar PLA
results were obtained with B cells of three different donors
(Figures 4g and h). These results confirm the interaction of
CD40-Fas and CD40-TRAILR2 interactions
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CD40 with Fas or with TRAILR2 on activated human
B-lymphocytes.
Signalling-incompetent TRAILR2 or Fas decreases CD40
signalling. We wanted to determine whether heteromeriza-
tion of CD40 with TRAILR2 or Fas could modulate CD40-
mediated NF-κB activation. However, Fas and TRAILR2 can
also induce NF-κB activation26 and overexpression of Fas or
TRAILR2 may indirectly impact on CD40 signals by inducing
cell death. To rule out any direct contribution of Fas and
TRAILR2 to NF-κB signalling, we used glycolipid-anchored
constructs of these receptors lacking transmembrane and
intracellular domains,27 and observed how these truncated
receptors may change CD40-mediated signals. 293T cells
were transfected with a constant amount of CD40 and CD40L
together with increasing concentrations of glycosyl-
phosphatidylinositol (GPI)-anchored CD40, TRAILR2, Fas
or TACI ectodomains, and the NF-κB response was quantified
using a luciferase reporter. As expected, increasing concen-
trations of CD40-GPI inhibited CD40 signalling, most
probably by competition for CD40L binding. However,
increasing concentrations of TRAILR2-GPI, which is unable
to compete for CD40L binding, also inhibited CD40 signalling.
A similar result was observed with higher amounts of Fas-GPI
but no impact in CD40 signalling was observed upon
expression of TACI-GPI (Figure 5a, left). None of these
receptors (CD40-, Fas- or TRAILR2-GPI) had an effect on
TACI-induced NF-κB response, indicating a specific impact
on CD40 signalling (Figure 5a, right). The amount of
transfected plasmid sufficient to inhibit 50% of CD40-
induced NF-κB response was about 1.4 ng of CD40-GPI for
0.5 ng of full-length CD40. For TRAILR2-GPI, the amount of
transfected plasmid sufficient to inhibit 50% of CD40-induced
NF-κB response was about 11 ng per well. The differences
between the strength of TRAILR2-GPI and Fas-GPI-
mediated inhibition could be explained either by the
endogenous expression of TRAILR2 in 293T cells, or by
differences in the interaction affinities with CD40. The
expression levels of TRAILR2-GPI remained relatively con-
stant in the presence of either CD40 or TACI. Similarly,
expression levels of CD40 and TACI were insensitive to the
presence of TRAILR2-GPI (Figure 5b). In addition, TRAILR2-
GPI did not impact on CD40–CD40L interaction, as deter-
mined by flow cytometry staining using Flag-tagged CD40
ligand (Figure 5b). Full-length CD40 and CD40-GPI showed
similar expression levels on the cell surface when the same
amount of plasmid was transfected (Figure 5c). Finally, GPI-
anchored receptors were all expressed at similar levels
(Figure 5c).
Figure 1 CD40 interacts with Fas and TRAILR2. (a) Flow cytometry FRET assay between CD40, Fas and TACI. The image shows the combination of the three receptors
fused to ECFP and EYFP. The gate used to calculate the percentage of FRET-positive cells was established by using a ECFP-EYFP fusion protein (100% FRET blue dots)
together with a ECFP/EYFP co-transfection (0% FRETred dots), bottom left panel. Bottom right panel shows the mean value of FRET-positive cells and SEM of five independent
experiments. (b) Flow cytometry FRET screening for different TNFRSF members expressed in B cells. (c) Flow cytometry FRETassay between CD40, Fas, TRAILR2 and TACI
lacking the intracellular domain (ΔICD). In all cases, FRET+ corresponds to the positive FRET reporter (ECFP–EYFP fusion protein) and FRET- corresponds to the negative
control (ECFP/EYFP co-transfection). The dotted line represents background FRET levels
CD40-Fas and CD40-TRAILR2 interactions
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It was shown that the cysteine-rich domain 1 (CRD1) of
Fas,18 TRAILR220 and CD4023 mediates receptor self-
assembly. In contrast to Fas-GPI, Fas-ΔCRD1-GPI did not
interfere with CD40-mediated NF-κB activation, suggesting
that the CRD1 of Fas may be involved in Fas-CD40 interaction
(Figure 5d). No conclusive results could, however, be obtained
with TRAILR2-ΔCRD1-GPI because this protein did not reach
the cell surface, most probably due to folding problems similar
to those reported when the CRD1 of CD40 was deleted or
modified.23 Taken together, these results indicate that the
extracellular domains of Fas and TRAILR2, but not that of
TACI, negatively affect CD40L-mediated signalling in the
absence of any direct contribution of Fas or TRAILR2 to the
signal or detectable changes in the levels of CD40 expression
or its ability to interact with CD40L.
Endogenous TRAILR2 or Fas modulate CD40 signalling.
To address the impact of endogenous Fas and TRAILR2 on
CD40 signalling, we generated several clones of BJAB cells
knocked-out for each of these receptors using the CRISPR/
Cas9 system28 (Supplementary Figure 3). When tested for
their ability to respond to CD40L, all Fas and TRAILR2 KO
clones showed a significant, dose-dependent increase in
CD40L-induced NF-κB response when compared with
wild-type cells, whereas CD40 KO BJAB clones were, as
expected, not responsive to CD40L stimulation (Figures 6a
and b). These changes in the NF-κB response strongly
suggest that CD40-Fas and CD40-TRAILR2 heteromeriza-
tion regulates CD40 signalling, even if it is difficult to exclude
that the absence of Fas or TRAILR2 may indirectly modulate
this outcome.
In primary human B cells, the expression profile and the
balance between CD40 and Fas signalling has been well
described,1 however, the expression and function of TRAILR2
remains poorly explored in B-cell subsets. We found that
primary human marginal zone B cells (MZ: CD27+ IgD+)
express higher levels of TRAILR2 compared with switched
memory cells (SM: CD27+ IgD-), whereas the expression of
CD40 and Fas was similar in these two B-cell populations
(Figures 6c, e and g). This difference was enhanced after
Figure 2 CD40, Fas and TRAILR2 colocalize at the surface of human B cells. Immunostainings of CD40-FAS and CD40-TRAILR2 in BJAB TRAILR2-positive (pos) and BJAB
TRAILR2-negative (neg) cell lines. Scale bars correspond to 20 and 5 μm in the main image and the inset, respectively. Fluorescence intensity plots across sections are shown in
Supplementary Figures 1 and 2
CD40-Fas and CD40-TRAILR2 interactions
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stimulation with CD40L+IL-21, with a peak of TRAILR2, Fas
and CD40 expression at day 2 (Figures 6d, f and h). To study
the impact of TRAILR2 expression on CD40 activation, we
used CFSE-labelled cells to analyze the proliferative response
of CD27+ B cells to CD40L stimulation. After 6 days of
activation, TRAILR2 high cells did not proliferate as strongly as
TRAILR2 low cells. A similar response was observed in four
independent donors (Figures 6i-k). Phosphorylation of the
NF-κB subunit p65/RelAwasmeasured by flow cytometry as a
marker of NF-κB activation in response to stimulation with
CD40L. The percentage of phospho-p65-positive cells was
significant higher in switched memory cells (that have lower
levels of TRAILR2) than in marginal zone B cells (that have
higher levels of TRAILR2) (Figure 6l). Taken together, these
results suggest that endogenous TRAILR2 may increase the
threshold required to obtain CD40L-induced responses in cell
lines and in primary human B cells.
Discussion
There are increasing evidences suggesting that TNFR
superfamily members are organized in the cell membrane as
ligand-independent oligomers rather than as individual recep-
tors. Different receptors of the family have been described
forming homo-dimers or -trimers, such as TNFR1 and 2,19
Fas,18 TRAIL receptors,20 CD4023 and BAFFR.29 This pre-
ligand assembly was reported in most cases to favour ligand
binding and normal signalling.18–20,29 However, the potential
heteromerization of TNFRs remains poorly explored and there
are only three studies addressing this phenomenon, one
between TRAILR2 and TRAILR420 and two others in the
context of the central nervous system that describe the
interaction of DR6 with p75NTR30 and DR6 with TROY.31 From
the screening performed by flow cytometry FRETusing CD40
as bait, we consistently found high FRETrates with Fas and to
a lesser extent with TRAILR2. Other receptors important for
B-cell survival and differentiation were negative in this
screening. These interactions did not require the presence
of the intracellular domain, which is in line with the fact that
most of the TNFRSF–TNFRSF interactions described to date
rely on the extracellular region of the receptors.
CD40-Fas and CD40-TRAILR2 interactions take place at the
endogenous levels in theBurkitt B-cell lymphomaBJAB cell line
expressing or not TRAILR2. Interestingly, the CD40–Fas
Figure 3 CD40 selectively interacts with TRAILR2 over Fas. (a) Co-immunoprecipitation of CD40, Fas and TRAILR2 in BJAB TRAILR2-negative (neg) and TRAILR2-positive
(pos) cells followed by WB detection of CD40, Fas and TRAILR2. (WMF: input of whole membrane fraction). (b) FACS expression profile of CD40 and Fas or CD40 and TRAILR2
on BJAB cell line TRAILR2-negative (left panel) together with a confocal image of the same cell type analyzed by PLA (right panel) for both CD40-Fas or CD40-TRAILR2
interactions. (c) Same as panel B, for the TRAILR2-positive BJAB cell line. (d) Mean and S.E.M. of the PLA assay. Spot numbers per cell were counted in the focal plane. The
number of cells analyzed by PLA is indicated on each image in panels b and c. Scale bars in panels c and d correspond to 10 μm
CD40-Fas and CD40-TRAILR2 interactions
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Figure 4 CD40 interacts with Fas and TRAILR2 in primary human B cells. (a) FACS expression profile of CD40 and Fas on primary human B cells non stimulated (NS),
activated with PMA-ionomycin (PI) or activated with anti-BCR plus CD40L (BC) (left panels) together with a confocal image of the same cell type analyzed by PLA for CD40-Fas
interaction (right panels) (one representative image out of three independent donors is shown). (b) Percentage of CD40-Fas double-positive cells in five different donors treated as
described in panel a. (c) Mean and S.E.M. of the PLA assay for the three donors analyzed by PLA. Spot numbers were counted in positive cells in the focal plane. (d, e and f)
Same as a–c, but for CD40–TRAILR2 interactions. The number of cells analyzed in the example is indicated on each image. Scale bars correspond to 5 μm. (g) HLA-DR and
isotype control mean fluorescence intensity (MFI) and S.E.M. of five different human primary B cells samples that were either NS, activated with PI or activated with anti-BCR plus
CD40L (BC). (h) Same as g, but for CD86 detection
CD40-Fas and CD40-TRAILR2 interactions
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interaction was only detected in TRAILR2-negative BJAB cells
despite similar expression levels of CD40 and Fas in both cell
lines, indicating a possible competition between TRAILR2 and
Fas for CD40 binding. This competition at the endogenous
levelswas evidenced by co-immunoprecipitations and by PLAs.
However, the molecular basis for the observed selectivity in
Figure 5 Heteromer formation with signalling-incompetent TRAILR2 or Fas has a negative impact on CD40 signalling. (a) NF-κB luciferase assay in 293T cells transiently
transfected with 0.5 ng of CD40, 1 ng of CD40L (left panel) or with 0.5 ng of TACI, 1 ng of BAFF (right panel) and increasing amounts of GPI-anchored CD40, TRAILR2, Fas or
TACI. One out of three independent assays with similar results is shown. (b) Flow cytometry analysis of TRAILR2-GPI, CD40 full-length and TACI full-length surface expression.
(c) Left: surface expression levels of CD40 full-length, CD40-GPI and CD40 full-length in the presence of TRAILR2, detected by staining with Flag-CD40L. Right, surface
expression levels of CD40-GPI and TRAILR2-GPI, detected by staining with an anti-TRAILR3 mAb recognizing the GPI-proximal region of the fusion receptors. MFI, mean of
fluorescence intensity. (d) NF-κB luciferase assay in 293T cells transiently transfected with 0.5 ng of CD40, 1 ng of CD40L and increasing amounts of GPI-anchored Fas,
Fas-ΔCRD1, CD40 and TACI. One out of two independent assays with similar results is shown. (e) Flow cytometry analysis of Fas and Fas-ΔCRD1 surface expression
CD40-Fas and CD40-TRAILR2 interactions
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these interactions remains unclear. CD40 may have a higher
affinity for TRAILR2 than for Fas, but these interactions may
also be influenced by the relative abundance of each receptor
on the cell surface. Finally, we cannot exclude that Fas or
TRAILR2 may localize to specialized membrane micro-
domains in which CD40 could be recruited.
PLA studies confirmed that both CD40-Fas and CD40-
TRAILR2 are close together in primary human B cells. In these
Figure 6 Endogenous TRAILR2 or Fas modulate CD40 signalling. (a) NF-κB response of wild-type, Fas KO, TRAILR2 KO and CD40 KO BJAB cell lines induced by the
indicated concentrations of Flag-ACRP-CD40L (mega-CD40L). One out of two independent experiments is shown (b). Average of the different clones and replicates of each KO
cell line stimulated with 1 μg/ml of mega-CD40L. (c) Ex vivo expression profile of CD40 in marginal zone (MZ) and switched memory (SM) primary human B cells. (d) Expression
profile of CD40 in MZ and SM along 6 days of CD40L+IL-21 stimulation. (e and f) Same as c and d, but for Fas expression. (g and h) Same as c and d, but for TRAILR2
expression. MZ B cells are gated as CD27+, IgD+ and SM B cells are gated as CD27+ IgD-. The mean and S.E.M. of six independent experiments is shown. (i) TRAILR2
expression in CD27+ B cells of one representative donor out of four tested after six days of stimulation with CD40L+IL-21. The same gating was used in panel j. (j) CFSE
proliferation profile of TRAILR2 low CD27+ (grey histogram) and TRAILR2 high CD27+ (black line) primary human B cells of one representative donor out of four tested after six
days of stimulation with CD40L+IL-21. (k) Average proliferative response for the four independent donors analyzed. (l) Flow cytometry analysis of phospho-p65 (RelA) after 5-min
stimulation with CD40L. The figure shows five independent donors analyzed in duplicate
CD40-Fas and CD40-TRAILR2 interactions
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experiments, CD40 was expressed in all conditions, and it was
possible to preferentially induce Fas or TRAILR2 using
different activation protocols. Cells in both stimulation condi-
tionswere not exactly comparable: Fas expression levelswere
different, and CD40 was engaged by ligand in one but not the
other condition. Nonetheless, the results are fully compatible
with a model in which CD40 preferentially interacts with
TRAILR2 rather than with Fas. The preferred interaction
between CD40 and TRAILR2 may thus be common to
lymphoma cell lines and primary cells.
We have shown that expression of signalling-incompetent
TRAILR2 or Fas, unable to interact with CD40L, decreased or
sometimes totally abolished the ability of full-length CD40 to
respond to CD40L with NF-κB activation. Under these
conditions, surface expression of CD40, and its ability to bind
CD40L were unaffected, indicating that heteromers interfere
with the signalling function by acting downstream of ligand
binding, probably by interfering with formation of a functional
signalling complex. Surface expression of full-length and GPI-
anchored CD40 was similar, allowing comparisons to be
performed. At the amount of transfected plasmid DNA
sufficient for a 50% inhibition of CD40-induced NF-κB
response, CD40-GPI was in a 3-fold excess over full-length
CD40, and TRAILR2-GPI was in a 20-fold excess, which
appears to be within a physiological range, especially when
considering that the GPI fusion receptors may not be optimal
for heteromer formation. In the case of TRAILR2-GPI, we
carefully excluded the possibility of artefactual quenching of
CD40L or CD40, suggesting that the observed effects are due
to heteromer formation. It is tempting to speculate that the
combined outcome of signalling via CD40 on the one hand,
and TRAILR2 and Fas on the other hand, is not only regulated
intracellularly by activation of pro- or anti-apoptotic signalling
pathways, but also directly at the level of receptors whose
relative expression levels may determine whether they can be
activated or not. For several TNFRs, a pre-ligand assembly
domain (PLAD) has been described that mediates homo-
interactions.18–20,23 The deletion of the CRD1 of Fas was
sufficient to abrogate its inhibitory effect on CD40 signalling
indicating that the PLAD of Fas may have a role in heteromer
formation. However, TRAILR2 with a similar deletion did not
reach the cell surface, precluding interpretation of whether
TRAILR2 CRD1 is involved or not in heteromer interactions.
The inhibitory impact of Fas and TRAILR2 on CD40 signalling
has been confirmed in Fas and TRAILR2 KO BJAB cell lines,
which showed increased responsiveness to CD40L.
In the biology of B cells, Fas and TRAILR2 are death
receptors that trigger apoptosis of autoreactive and/or
activated B cells,32,33 whereas CD40 is a potent NF-κB
activator that provides activation and proliferation signals.34,35
However, the interplay between these three receptors is
complicated and not fully understood. Several studies focused
on the role of Fas during high-affinity B-cell selection in GC
showing that Fas has an essential role in GC B-cell apoptosis
both in vitro36 and in vivo.6 During B-cell maturation, somatic
hypermutations are introduced in the variable regions of heavy
and light chains of the BCRwith the aim of generating antigen-
specific B cells of higher affinity.37 A stringent selection
mechanism takes place to ensure the survival of antigen-
specific high-affinity B cells and the death of low-affinity or
autoreactive B cells. GC B cells express CD40 and Fas and
undergo FasL-mediated apoptosis, unless a survival signal is
provided by BCRor CD40 engagement.38–41 The same type of
data does not exist for TRAILR2, but it was shown ex vivo on
primary human B cells that BCR and/or CD40L signals can
rescue naive B cells, but not memory B cells, from TRAIL-
induced apoptosis.13 Together, these data suggest that
signals transduced by Fas, TRAILR2 and CD40 are entangled
to finely control the fate of B cells. In B-cell lymphomas, the
relationship between CD40, Fas and TRAILRs appears even
more complicated. As in normal GC B-lymphocytes, CD40
rescues apoptosis induced by Fas in low-grade B lymphoma,
but CD40 sensitizes Burkitt lymphoma B cells to Fas-induced
apoptosis.42–44 In a similar way, CD40 triggering protects
Burkitt lymphoma13 and follicular lymphoma,45,46 but sensi-
tizes chronic lymphocytic leukaemia B cells to apoptosis
induced by TRAIL.47 The measure of TRAILR2 expression
revealed that expression of this receptor is increased in
marginal zone compared with switched memory B cells and
that this difference is maintained upon CD40L+IL-21 stimula-
tion. Our in vitro data would be in line with the notion that
TRAILR2 negatively regulates CD40L effects, as its expres-
sion inversely correlated with CD40L-induced proliferation in
primary human B cells. Accordingly, CD40L-induced phos-
phorylation of p65 (RelA) inversely correlated with TRAILR2
expression in primary human B cells. This was true when
analyzing percentage of phospho-p65-positive cells, but was
not as marked when analyzing mean fluorescence intensities,
suggesting that TRAILR2 may increase the threshold of
CD40L stimulation required to activate CD40, but may not
modify signalling once CD40 has been activated.
At this stage of the study, experiments performed in primary
cells correlate TRAILR2 expression with lower responses to
CD40L (NF-κB and proliferation). It would be interesting in the
future to knock-out TRAILR2 from primary human B cells and
test whether this increases responsiveness to CD40L, or to
produce a mouse model with inducible knock-out of TRAILR.
Mice, however, display significant differences with human in
their array of TRAIL receptors,48 and it would be necessary to
test first whether TRAILR–CD40 interactions also take place
in mice.
In conclusion, our results reveal that ligand-independent
heteromer formation between different TNFRSF members
may be involved in the modulation of very early steps of
activation, upstream of their signalling pathways.
Materials and Methods
Cell lines. BJAB cells expressing TRAILR2 or not were grown in RPMI 1640
medium (Lonza, Verviers, Belgium) supplemented with 10% foetal calf serum and
5 μg/ml each of penicillin and streptomycin. HEK 293T cells were grown in DMEM
medium (Gibco, Carlsbad, CA, USA) supplemented with 10% foetal calf serum.
BJAB Fas KO, BJAB TRAILR2 KO and BJAB CD40 KO were generated by lentiviral
transduction using CRISPR/Cas9 expression vectors carrying the corresponding
gRNAs (Supplementary Table S1), according to Shalem et al.28
Antibodies and TNF ligands. Western blot: anti-CD40 S-17 (Santa Cruz
Biotechnology, Dallas, TX, USA), anti-Fas (ZB4) (Abcam, Cambridge, UK), anti-DR5
(Millipore, Billerica, MA, USA). Immunoprecipitations: anti-CD40 C20 agarose
conjugate (Santa Cruz Biotechnology), anti-Fas (C20) (Santa Cruz Biotechnology),
anti-DR5 D4E9 (Cell Signalling, Danvers, MA, USA). Flow cytometry: anti-CD40-
FITC and –PE-Cy5 (5C3), anti-Fas-PE (DX2), anti-MHC-II-FITC (Tü 39), anti-CD86-
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PE (2331) and anti-CD19-V500 (HIB19) (BD Pharmingen, San Diego, CA, USA); anti-
CD27-BV421, anti-CD95-AF647 and anti-IgD-PE-Cy7 (Biolegend, San Diego, CA,
USA); anti-DR5-PE (B-K29) (Diaclone Research, San Diego, CA, USA) for cell lines;
anti-TRAILR2 PE (eBioscience, San Diego, CA, USA) for primary cells; anti-TRAILR2
(TR2.21; to screen TRAILR2 KO BJAB clones) (Adipogen, Lausen, Switzerland); anti-
phospho-NF-κB p65 (Ser536, clone 93H1)-AF647 (Cell Signalling). Flag-ACRP-hBAFF,
Flag-ACRP-hCD40L and Flag-ACRP-FasL were produced in house and staining were
performed as described in Bossen et al.27 Flag-ACRP-hCD40L (mega-CD40L) was
obtained from Adipogen. Anti-TRAILR3 (LEIA) was used for GPI recognition (own
production).27 Microscopy and PLA: monoclonal rabbit anti-CD40 (EBI-19-21) (Abcam),
mouse anti-DR5 (DJR2-4) (ABD Serotec, Raleigh, NC, USA) and mouse anti-CD95
(DX2) (BD Biosciences, San Diego, CA, USA).
Expression plasmids. See Supplementary Table 1.
Förster resonance energy transfer. Experiments were performed using a
LSRII flow cytometer instrument (BD Biosciences). EYFP signal was recorded using
the 488 nm laser with a 530/30 filter, ECFP signal was recorded using the 405 nm
laser with a 450/50 filter and FRET signal was recorded using the 405 nm laser with
a 585/42 filter. For each condition, we evaluated a minimum of one thousand -ECFP
-EYFP double-positive cells. HEK 293T cells were transiently transfected with ECFP
and EYFP fusion receptors and analyzed 16–20 h post-transfection. Positive
FRET cells were gated using an ECFP–EYFP fusion protein as positive control and
a co-transfection of ECFP and EYFP as negative control according to Banning
et al.49 and Schneider et al.50
Immunocytochemistry. BJAB cells grown on Lab-tek chambers were fixed
with 2% formaldehyde and incubated with primary antibodies overnight at 4 °C
(rabbit anti-CD40 50 μg/ml, mouse anti-TRAILR2 25 μg/ml or biotinylated mouse
anti-Fas 1/10) in 1% normal goat serum. Cells were then incubated for 1 h with F
(ab)’2 goat anti-rabbit-A488 (1/200) plus mouse-A594 (1/200) or in F(ab)’2 goat
anti-rabbit-A488 (1/200) plus streptavidin A546 (1/1000) for the detection of CD40-
TRAILR2 or CD40-Fas, respectively. After post-fixation in 4% formaldehyde, nuclei
were counterstained with DAPI (1/500). Slides were then mounted with Dako
fluorescent medium (Glostrup, Denmark) and images were acquired using a LSM
510 Laser Scanning Microscope (Carl Zeiss, Jena, Germany).
Immunoprecipitations. In all, 1 × 107 TRAILR2-negative and TRAILR2-
positive BJAB cells were harvested and the native membrane fraction was obtained
using ProteoExtract kit (Calbiochem, San Diego, CA, USA). Immunoprecipitations
were performed with agarose-conjugated anti-CD40 antibody or protein A-loaded
antibodies (Fas and TRAILR2) as described in Schneider et al.50 Immunopreci-
pitates and whole membrane fractions were resolved on 10% acrylamide SDS gels
before electrophoretic transfer onto nitrocellulose and western blot analysis.
Duolink in situ PLA. PLA analysis was performed according to the
manufacturer’s instructions (OLink Biosciences, Uppsala, Sweden). Briefly, cells were
incubated for 1 h at 37 °C on poly-lysine coated slides, fixed with 2% formaldehyde and
blocked with 2% of normal donkey serum. Primary antibodies (used at the same
dilutions than for immunocytochemistry) were incubated overnight at 4 °C, cells were
then incubated with PLUS and MINUS secondary PLA probes against both rabbit and
mouse IgG. Hybridization and ligation steps followed the incubation, and then
amplification was performed. After mounting with Duolink mounting medium, images
were acquired using a LSM 700 Laser Scanning Microscope in the larger focal plane of
each cell (Carl Zeiss). Quantification was done using ImageJ.51
Human B-cell purification and culture. Peripheral blood mononuclear
cells were first isolated using Ficoll (Sigma, St. Louis, MO, USA). Then,
B-lymphocytes were purified by negative magnetic sorting (MACS) using the human
B-cell purification kit from Miltenyi Biotec (Paris, France). Cells were then incubated
in RPMI-1640 supplemented with 10% foetal calf serum and 5 μg/ml each of
penicillin and streptomycin for 24 h and treated as follows: 50 ng/ml PMA (phorbol-
myristate-acetate) (Sigma-Aldrich, St. Louis, MO, USA) and 1 mM ionomycin
(Sigma-Aldrich) or 0.5 ng/ml hCD40L-muCD8 (Ancell, Bayport, MN, USA) and
20 μg/ml of anti-IgM/IgG (Sigma-Aldrich). Cells were then subjected to flow
cytometry and PLA analysis. For CD40, Fas and TRAILR2 expression analysis,
MACS sorted B cells (1.5 × 105 cells/ml) were stimulated with CD40L and IL-21 in
enriched Iscove´s medium supplemented with 10% FCS, 1 μg/ml insulin, 2.5 μg/ml
apo-transferrin, 0.1% fatty acid supplement, 1% non-essential amino acids, 2 mM
glutamine and 1 μg/ml reduced glutathione as described.52 B cells were stained and
analyzed by flow cytometry at the indicated time points.
Flow cytometry. Phenotype of human B cells was determined with the
following antibodies: CD19-V500, CD40-PE-Cy5, CD27-BV421, CD95-AF647, IgD-
PE-Cy7, TRAILR2 PE. Dead cell exclusion was performed by Live/Dead staining kit
(Invitrogen, Molecular Probes, Carlsbad, CA, USA), following the manufacturer
instruction. B-cell proliferation was monitored by CFSE (carboxyfluorescein
diacetate, succinimidyl ester; Molecular Probes) labelling. Phospho-p65 was
determined as follows: 1–2 × 105 magnetically isolated CD27+ B cells were seeded
in 100 μl of medium in a 96-well plate, incubated for 1 h, and then stimulated with
CD40L for 5 min. Cells were then fixed with Cytofix (Becton Dickinson, Franklin
Lakes, NJ, USA) and incubated for 10 min at 37 °C. After washing, cells were
stained for surface markers for 15 min in ice. Afterwards the cells were washed and
permeabilized by drop-wise addition of 50 μl ice-cold Phosflow Perm Buffer III
(Becton Dickinson), gentle vortexing and incubation on ice for 30 min. This was
followed by two more washing steps, and staining for intracellular phospho-NF-κB
p65 (Ser536). The data were acquired with BD FACS Canto II (Becton Dickinson)
and were analyzed with FlowJo software version 8.7 (TreeStar Inc., Ashland,
OR, USA).
Luciferase reporter assay. HEK293T cells were cultured in 96-well plates at
3 × 105 cells/ml in 100 μl. After 24 h, cells were transfected with a mix of vectors
containing: EGFP (transfection efficiency control) (7 ng), control Renilla vector
(7 ng), NF-κB firefly luciferase reporter vector (7 ng), CD40 (0.5 ng), CD40L (1 ng)
and increasing concentrations of GPI-anchored CD40, TRAILR2, Fas or TACI (0 to
34 ng) (70 ng per well total DNA), using Polyfect transfection reagent
(Qiagen, Hilden, Germany). After 24 h, cells were lysed and expression of firefly
and renilla luciferases was detected with the dual luciferase assay detection kit
(Promega, Madison, MI, USA).
Statistical analysis. FRET experiments were analyzed using unpaired t-test,
and when multiple receptors where compared using one-way ANOVA with Tukey's
post-test. PLA on BJAB cells was analyzed using unpaired t-test. PLA on B cells
was analyzed using one-way ANOVA (non parametric Kruskal–Wallis test) with
Dunn post-test. NF-κB luciferase reporter assay in BJAB cells was analyzed using
one-way ANOVA with Tukey post-test. Differences between marginal zone and
switched memory B cells were analyzed using unpaired t-test. All analyses were
performed using GraphPad Prism version 5.00 for Windows, GraphPad Software,
San Diego, CA USA; www.graphpad.com.
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